From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Acute Myeloid Leukemia: Time for New Research Paradigms?

Although molecular and immunological cancer therapies have made great strides across the clinical landscape in recent years, their use in treating acute myeloid leukemia...
WIB_icon

Ibrutinib-Chemoimmunotherapy Combo Adds to CLL Therapy

In chronic lymphocytic leukemia (CLL), combining two effective treatments enhances their clinical activity, according to early study results published recently in Blood. Treatment-naive CLL patients...
WIB_icon

Rituximab Plus Recombinant Human Thrombopoietin: Fast Results in Immune Thrombocytopenia

Although corticosteroids or intravenous immunoglobulin are typical first- and second-line treatments for immune thrombocytopenia (ITP), about one-third of patients do not respond to these...
WIB_icon

MDS/MPN Overlap: The Time is Now for Uniform Response Criteria

Myelodysplastic syndromes (MDS)/myeloproliferative neoplasms (MPNs) are clonal myeloid disorders possessing both dysplastic and proliferative features that cannot be classified as one or the other...
WIB_icon

A Surprising Conclusion: High-Cost Blood Cancer Treatments May Be Cost-Effective

Although the past 15 years have seen great progress in the treatment of hematologic malignancies, these innovative therapies have left payers and patients with...
WIB_icon

Low-Molecular-Weight Heparin Fails to Boost Live Birth Rates in Women with Recurrent Miscarriage

Antithrombotic medications are often prescribed to women with histories of unexplained recurrent miscarriages, although there is little evidence of the efficacy of this approach....
WIB_icon

Ibritumomab Tiuxetan Ups Survival in Tough-to-Treat Diffuse Large B-Cell Lymphoma

Many patients with aggressive B-cell non-Hodgkin lymphoma (NHL) are cured of the disease after short-course chemotherapy and radiation. Certain adverse risk factors, though, make relapse more likely. Ibritumomab tiuxetan as add-on...
WIB_icon

Brentuximab Vedotin Active in Relapsed/Refractory B-Cell Lymphoma

For patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for transplant or fail to respond to salvage regimens, treatment with brentuximab...
WIB_icon

Superficial Vein Thromboses Put People at Risk for Subsequent Blood Clots

Until recently, a superficial vein thrombosis (SVT) was seen as a painful induration of limited clinical significance. New evidence from a large population-based study...
WIB_icon

Brentuximab Vedotin: Changing the Landscape for Relapsed/Refractory Hodgkin Lymphoma Patients?

For the approximately 50 percent of patients with relapsed/refractory Hodgkin lymphoma who do not respond to autologous stem cell  transplantation (auto-SCT), the antibody-drug conjugate brentuximab vedotin produced durable response and survival, according to...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.